Trade Lenz Therapeutics Inc - LENZ CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.001 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 16.34 |
| Open | 16.51 |
| 1-Year Change | 409.57% |
| Day's Range | 16.14 - 16.51 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| May 3, 2024 | 16.45 | 0.02 | 0.12% | 16.43 | 16.63 | 16.14 |
| May 2, 2024 | 16.34 | 0.45 | 2.83% | 15.89 | 16.40 | 15.30 |
| May 1, 2024 | 15.74 | 0.21 | 1.35% | 15.53 | 16.15 | 15.49 |
| Apr 30, 2024 | 22.12 | 0.00 | 0.00% | 22.12 | 22.12 | 22.12 |
| Apr 15, 2024 | 22.12 | 0.00 | 0.00% | 22.12 | 22.12 | 22.12 |
| Apr 2, 2024 | 22.12 | 0.00 | 0.00% | 22.12 | 22.12 | 22.12 |
| Mar 22, 2024 | 22.12 | 0.00 | 0.00% | 22.12 | 22.12 | 22.12 |
| Mar 21, 2024 | 3.16 | 0.02 | 0.64% | 3.14 | 3.20 | 3.03 |
| Mar 20, 2024 | 3.25 | 0.30 | 10.17% | 2.95 | 3.26 | 2.92 |
| Mar 19, 2024 | 3.03 | -0.13 | -4.11% | 3.16 | 3.16 | 2.59 |
| Mar 18, 2024 | 3.23 | 0.01 | 0.31% | 3.22 | 3.29 | 3.08 |
| Mar 15, 2024 | 3.30 | 0.13 | 4.10% | 3.17 | 3.32 | 2.94 |
| Mar 14, 2024 | 3.46 | -0.13 | -3.62% | 3.59 | 3.59 | 3.32 |
| Mar 13, 2024 | 3.54 | -0.12 | -3.28% | 3.66 | 3.85 | 3.47 |
| Mar 12, 2024 | 3.37 | -0.21 | -5.87% | 3.58 | 3.67 | 3.21 |
| Mar 11, 2024 | 3.71 | 0.22 | 6.30% | 3.49 | 4.23 | 3.39 |
| Mar 8, 2024 | 3.10 | -0.02 | -0.64% | 3.12 | 3.23 | 3.10 |
| Mar 7, 2024 | 3.10 | 0.11 | 3.68% | 2.99 | 3.14 | 2.94 |
| Mar 6, 2024 | 3.06 | -0.12 | -3.77% | 3.18 | 3.18 | 3.02 |
| Mar 5, 2024 | 3.20 | -0.09 | -2.74% | 3.29 | 3.40 | 3.17 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Graphite Bio, Inc. Company profile
About Graphite Bio Inc
Graphite Bio, Inc. is clinical-stage, gene editing company. The Company is developing a new class of therapies to cure a range of serious and life-threatening diseases. The Company's gene editing platform allows to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. The Company's lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. The Company's pipeline includes multiple programs including its gene replacement program, GPH201 for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene prevent normal immune system function, and targeted gene insertion program, GPH301 for Gaucher disease, and multiple additional programs in both HSCs and other cell types.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Graphite Bio Inc revenues was not reported. Net loss increased 3% to $70.8M. Higher net loss reflects Research and development - Balancing val increase from $9M to $35.2M (expense), General and administrative - Balancing v increase from $4.3M to $17.3M (expense), Stock-based Compensation in SGA increase from $54K to $5.2M (expense).
| Industry: | Bio Therapeutic Drugs |
611 Gateway Blvd, Suite 120
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com